Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday

Coherus Oncology (NASDAQ:CHRS) is projected to release its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Coherus Oncology to announce earnings of ($0.22) per share and revenue of $15.90 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.06. The business had revenue of $14.31 million for the quarter, compared to analysts’ expectations of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. On average, analysts expect Coherus Oncology to post ($0.88) EPS for the current fiscal year and ($0.83) EPS for the next fiscal year.

Coherus Oncology Stock Performance

NASDAQ:CHRS opened at $0.83 on Monday. The firm has a market cap of $128.25 million, a PE ratio of -0.81 and a beta of 1.03. The stock has a fifty day moving average price of $1.20 and a 200 day moving average price of $1.53. Coherus Oncology has a 12-month low of $0.81 and a 12-month high of $2.62. The company has a current ratio of 1.77, a quick ratio of 1.70 and a debt-to-equity ratio of 0.61.

Key Headlines Impacting Coherus Oncology

Here are the key news stories impacting Coherus Oncology this week:

• Positive Sentiment: New data for tagmokitug reportedly support advancing the program into a broader study. The update could improve investor confidence in Coherus Oncology’s pipeline and provide a potential catalyst if expanded testing confirms the treatment’s benefit. Coherus Oncology stock: Tagmokitug data support broader study
• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating. Its forecasts anticipate Coherus Oncology’s losses narrowing from an estimated $0.91 per share in fiscal 2026 to $0.63 in fiscal 2027, $0.48 in fiscal 2028 and $0.19 in fiscal 2029, before turning profitable at $0.19 per share in fiscal 2030. This projected improvement offers a longer-term bullish argument for the stock. HC Wainwright Initiates Coverage on Coherus Oncology
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for continued losses, including estimated EPS of negative $0.22 in Q3 2026 and negative $0.21 in Q4 2026, followed by losses ranging from $0.17 to $0.13 per share during 2027. The estimates provide a clearer outlook but do not imply near-term profitability.
• Negative Sentiment: HC Wainwright’s fiscal 2026 loss estimate of $0.91 per share is slightly worse than the broader consensus estimate of $0.87. Continued negative earnings could weigh on sentiment, particularly while CHRS remains well below its 50-day and 200-day moving averages and faces biotechnology-sector financing and execution risks.

Analysts Set New Price Targets

CHRS has been the topic of a number of analyst reports. Weiss Ratings raised Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. HC Wainwright initiated coverage on Coherus Oncology in a research report on Thursday. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Coherus Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.